2016
DOI: 10.1007/s00535-016-1274-1
|View full text |Cite|
|
Sign up to set email alerts
|

Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients

Abstract: In clinical practice, ADA was effective in UC, especially in anti-TNF naïve patients. FC and CRP could be predictors of treatment effectiveness.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

8
48
0
1

Year Published

2017
2017
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 59 publications
(57 citation statements)
references
References 33 publications
8
48
0
1
Order By: Relevance
“…For this reason, the target of the treatment has evolved from clinical improvement to mucosal healing, which has been associated with favourable long‐term outcomes in CD, including a reduction in the hospitalisations and in the need of corticosteroids . We found a negative correlation between initial endoscopic severity and the response to treatment, consistent with findings from another real‐world study with adalimumab in patients with ulcerative colitis . This could be associated with the need for a higher dose in patients more pronounced endoscopic activity at baseline—as has been shown for anti‐TNFα agents—which led to a change in the concept of primary failure with these agents …”
Section: Discussionsupporting
confidence: 83%
“…For this reason, the target of the treatment has evolved from clinical improvement to mucosal healing, which has been associated with favourable long‐term outcomes in CD, including a reduction in the hospitalisations and in the need of corticosteroids . We found a negative correlation between initial endoscopic severity and the response to treatment, consistent with findings from another real‐world study with adalimumab in patients with ulcerative colitis . This could be associated with the need for a higher dose in patients more pronounced endoscopic activity at baseline—as has been shown for anti‐TNFα agents—which led to a change in the concept of primary failure with these agents …”
Section: Discussionsupporting
confidence: 83%
“…Anti-TNF therapy in IBD has been reported to result in better clinical outcomes in patients without anti-TNF experience than in patients with anti-TNF experience. [34][35][36] Our data also showed that previous anti-TNF experience was an independent negative predictor of long-term sustained clinical response to CT-P13 therapy in CD patients, although there was no significant differences in the cumulative retention rates of CT-P13 therapy between anti-TNF-naïve and switch patients. This discrepancy may be because that the sustained clinical response or remission could be assessed only in cases provided accurate and detailed information to evaluate clinical efficacy using CDAI or Mayo scores at the time of last follow-up.…”
Section: Discussionsupporting
confidence: 58%
“…Anti‐TNF therapy in IBD has been reported to result in better clinical outcomes in patients without anti‐TNF experience than in patients with anti‐TNF experience . Our data also showed that previous anti‐TNF experience was an independent negative predictor of long‐term sustained clinical response to CT‐P13 therapy in CD patients, although there was no significant differences in the cumulative retention rates of CT‐P13 therapy between anti‐TNF‐naïve and switch patients.…”
Section: Discussionsupporting
confidence: 55%
“…There is a lack of large real-life studies on the outcome and predictors of outcome of adalimumab treatment in ulcerative colitis. Except for a Spanish study by Iborra et al on 263 patients [14], there is no previous study with more than 90 patients [15][16][17][18] and most studies comprise fewer than 50 patients [19][20][21][22][23][24]. We here report a Swedish multicenter reallife cohort study of 118 patients.…”
Section: Discussionmentioning
confidence: 96%
“…Moreover, a steroid-free clinical remission was achieved by almost a third of the patients (32.2%). In other real-life studies, clinical response rates have varied from 29% to 80% and clinical remission rates from 26 to 50% [14][15][16][17]20,21,23,24]. It is difficult to compare the results from individual studies due to differences in design, selection of patients and study endpoints.…”
Section: Discussionmentioning
confidence: 99%